retatrutide d Triple Agonist (GLP-1/GIP/GCG) Retatrutide: Evidence, Safety & Options

10 mg retatrutide + 5 ml BAC: 2 mg/ml concentration (less concentrated, larger volumes to draw)

The co-infusion of PYY(3-36) and GLP-1 led to a synergistic effect with near-suppression of these areas, correlating with the suppression in appetite as assessed by food intake studies [42]

Newer formulations are emerging, including oral semaglutide drops and oral tirzepatide , but the injectable versions remain the standard for weight management

The most common adverse events were gastrointestinal and dose-related: diarrhea (27.4% / 33.5% / 33.6% at 4 / 9 / 12 mg vs 13.2% on placebo), nausea (13.7% / 20.8% / 28.0% vs 8.0%) and constipation (14.0% / 16.2% / 16.8% vs 9.4%)

After completing the injection, properly dispose of your needle in a sharps container

Abrahamsson N, Borjesson JL, Sundbom M, Wiklund U, Karlsson FA, Eriksson JW